We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+12.85%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$16.7M
Cap. Flow
-$16.5M
Cap. Flow %
-5.78%
Top 10 Hldgs %
46.84%
Holding
97
New
24
Increased
16
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$16.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
ESTA icon
Establishment Labs
ESTA
+$6.8M
5
KURA icon
Kura Oncology
KURA
+$6.54M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$16.8M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
3
MRK icon
Merck
MRK
+$12.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.75M
5
BLU
BELLUS Health Inc.
BLU
+$6.35M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
2 Miscellaneous 16.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.6B
$21.4M 7.46%
92,500
-500
-0.5% -$135K
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$17.5M 6.11%
550,000
+170,000
+45% +$5.22M
ESTA icon
3
Establishment Labs
ESTA
$2.18B
$14.5M 5.07%
211,608
+98,384
+87% +$6.8M
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$12.3M 4.31%
321,017
-655,004
-67% -$16.8M
MDGL icon
5
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$12.3M 4.28%
+53,100
New +$14.4M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$42.5B
$12M 4.21%
+1,600,000
New +$13M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.6M 4.04%
201,887
+66,024
+49% +$3.45M
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$11.5M 4.02%
1,050,118
-33,000
-3% -$307K
BIIB icon
9
Biogen
BIIB
$32.6B
$11.4M 3.98%
+40,000
New +$11.9M
KURA icon
10
Kura Oncology
KURA
$1.17B
$9.63M 3.36%
910,317
+553,030
+155% +$6.54M
VRNA
11
DELISTED
Verona Pharma
VRNA
$9.46M 3.31%
447,667
-5,154
-1% -$110K
ACLX
12
DELISTED
Arcellx
ACLX
$7.15M 2.5%
226,275
+23,441
+12% +$896K
PRTA icon
13
Prothena Corp
PRTA
$493M
$6.83M 2.38%
+100,000
New +$6.45M
BBIO icon
14
PUT
BridgeBio Pharma
BBIO
$14.6B
$6.47M 2.26%
376,000
-13,800
-4% -$208K
VKTX icon
15
PUT
Viking Therapeutics
VKTX
$3.98B
$5.67M 1.98%
350,000
+256,100
+273% +$5.37M
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$5.58M 1.95%
900,723
+216,596
+32% +$1.03M
ATXS
17
DELISTED
Astria Therapeutics
ATXS
$5.42M 1.89%
650,875
+121,506
+23% +$1.4M
ASND icon
18
Ascendis Pharma A/S
ASND
$17.5B
$5.16M 1.8%
57,760
+17,760
+44% +$1.55M
IMVT icon
19
Immunovant
IMVT
$8.03B
$4.93M 1.72%
+260,000
New +$4.85M
VKTX icon
20
Viking Therapeutics
VKTX
$3.98B
$4.86M 1.7%
300,000
-322,249
-52% -$6.75M
AZN icon
21
AstraZeneca
AZN
$252B
$4.29M 1.5%
30,000
– –
INZY
22
DELISTED
Inozyme Pharma
INZY
$4.19M 1.46%
751,796
– –
CYTK icon
23
Cytokinetics
CYTK
$10.2B
$4.08M 1.43%
125,148
-96,315
-43% -$3.56M
AUTL
24
Autolus Therapeutics
AUTL
$607M
$3.78M 1.32%
+1,589,017
New +$3.77M
IMTX icon
25
Immatics
IMTX
$1.42B
$3.46M 1.21%
+300,000
New +$2.8M
1
2 3 4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Affinity Asset Advisors held 97 positions worth $286M, down 5.5% from $303M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $16.5M in Q2 2023, closing 27 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, Affinity Asset Advisors opened a new position in Kyntra Bio worth $2.65M.

  • Affinity Asset Advisors's largest Q2 2023 buy was Kyntra Bio: 39,332 shares worth $2.65M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2023, an estimated $6.8M increase.
  • Affinity Asset Advisors's biggest Q2 2023 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $16.8M.
  • Affinity Asset Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $286M portfolio in Q2 2023.
  • Affinity Asset Advisors opened 24 new positions and closed 27 in Q2 2023.
  • Affinity Asset Advisors's portfolio value fell 5.5% quarter-over-quarter to $286M.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.